66 reports

However, challenges associated with the drug delivery are expected to impede growth to certain extent.

  • Antisense Technology
  • Gene Therapy
  • Therapy
  • United States
  • Market Size
  • Key Patents in the domain

Viral vectors dominate the gene delivery systems with maximum number of approved drugs.

  • Gene Therapy
  • United States
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Genzyme Corporation

Gene Therapy in CVMD

7012 7995 6236

One-time, non-surgical, intracoronary catheterbased delivery.

  • Gene Therapy
  • United States
  • AnGes MG, Inc.
  • Juventas Therapeutics, Inc.
  • ViroMed Co., Ltd.

ONE APPROVED GENE THERAPY, NEOVASCULGEN, USED PLASMID DNA; HOWEVER, THE DRUG IS PRESENTLY APPROVED ONLY IN RUSSIA AND UKRAINE.

  • Gene Therapy
  • United States
  • Market Size
  • Supply
  • Sanofi S.A.

AAVance is a single-arm trial aimed at evaluating the effectiveness of a one-time delivery of a recombinant adenoassociated virus vector rh. ## carrying the N-sulfoglucosamine sulfohydrolase (SGSH) gene.

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Abeona Therapeutics, Inc.
  • Feb 21, 2017: Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

" Bio-Path is developing a truly innovative platform that has the potential to transform antisense drug delivery, commented Dr.

  • Gene Therapy
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.

Bio-Path is preparing to submit an investigational new drug (IND) application for a Phase ## clinical trial evaluating BP## in lymphoma.

  • Antisense Technology
  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • United States

The drug candidate initiates a local and transient surge of VEGF-A expression and enable the delivery of genetic instructions to spur the production of VEGF-A.

  • Cardiology
  • Gene Therapy
  • United States
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.

IV delivery of ABO- ## induced clearance of lysosomal GAG storage in the CNS and somatic tissues The Phase I/ II study will involve two dose cohorts involving intravenous administration of the drug candidate and with a primary objective being determination of safety of the

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Abeona Therapeutics, Inc.

It is developed based on EV-based drug delivery technology.

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Sarepta Therapeutics, Inc.

" Importantly, the stabilization of deep brain architecture at ## year highlights the potential of intravenous route of delivery in accessing the basal ganglia to promote neural stabilization.

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Abeona Therapeutics, Inc.

Evox Therapeutics harnesses its proprietary EV-based drug delivery technology using advanced biomolecular engineering, technology and drug loading strategies to deliver protein biologics, antibody and nucleic acid-based drugs to tissues and organs including the br

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Genzyme Corporation
  • GENE THERAPY TO ACTIVATE HIF-1 ALPHA FOR WOUND AND ULCERS - DRUG PROFILE

The company' s proprietary plaftform is used in drug delivery, rapid detection of biowarfare agents, rapid detection of pesticides and immunogenicity tests for biotherapeutics among others.

  • Gene Therapy
  • Type 2 Diabetes
  • Wound Care
  • United States
  • ProMetic Life Sciences Inc.

No drug-related serious adverse events related to the drug were reported in subjects in the cohort receiving ABO-## (Cohort ##: ##E## vg/ kg) through over ##, ## cumulative follow-up days.

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Abeona Therapeutics, Inc.

(ArmaGen) received three new patents on IgG-neurotrophin fusion proteins for targeted brain drug delivery across the human blood-brain barrier (BBB) from US Patent Office.

  • Gene Therapy
  • Medical Biotechnology
  • Therapy
  • United States
  • Product Initiative

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

(ArmaGen) received three new patents on IgG-neurotrophin fusion proteins for targeted brain drug delivery across the human blood-brain barrier (BBB) from US Patent Office.

  • Gene Therapy
  • Neurological Disorder
  • Transplantation
  • United States
  • Shire plc

The company' s non viral delivery system is suited for delivering nucleic acid drugs that permits therapies for human diseases.

  • Dementia
  • Gene Therapy
  • Psychotic Disorder
  • United States
  • Product Initiative

It is developed using G-technology, a liposomal drug delivery system.

  • Gene Therapy
  • Medical Biotechnology
  • Pharmaceutical
  • United States
  • Product Initiative

(ArmaGen) received three new patents on IgG-neurotrophin fusion proteins for targeted brain drug delivery across the human blood-brain barrier (BBB) from US Patent Office.

  • Endocrine Disease
  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative

They have overcome many of the drug delivery issues previously seen in RNA products, and we believe Mirna has the potential to become one of the leading miRNA companies.

  • Gene Therapy
  • Therapy
  • United States
  • Corporate Finance
  • Pfizer Inc.

It provides design and delivery of therapeutic agents.

  • Gene Therapy
  • Wound Care
  • United States
  • Company
  • Product Initiative

THE DRUG CANDIDATE ACTS BY TARGETING RS##, A SINGLE NUCLEOTIDE POLYMORPHISM (SNP), (HTT SNP-##).

  • Dementia
  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative

The drug candidate acts by targeting the clarin-## (CLRN##).

  • Eye Disease
  • Gene Therapy
  • United States
  • Product Initiative
  • ProQR Therapeutics N.V.

It discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems.

  • Gene Therapy
  • Therapy
  • United States
  • Product Initiative
  • Promethera Biosciences S.A.

REP-## encodes rab-escort protein ## (REP##).

  • Gene Therapy
  • Healthcare
  • Pharmaceutical
  • United States
  • Company

It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient.

  • Gene Therapy
  • Hospital
  • United States
  • Product Initiative
  • Hemostemix, Ltd.

(ArmaGen) received three new patents on IgG-neurotrophin fusion proteins for targeted brain drug delivery across the human blood-brain barrier (BBB) from US Patent Office.

  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

It is based on the Peptelligence platform that comprises peptide oral drug delivery for the enhanced delivery of TXA-##.

  • Gene Therapy
  • Therapy
  • United States
  • Company
  • Product Initiative

Its technologies include therapeutics, diagnostics, drug delivery, research tools, medical devices, software, and educational materials.

  • Gene Therapy
  • Therapy
  • United States
  • Company
  • Abeona Therapeutics, Inc.